$Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin$
QR Code

QR Code

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin

Aim. To compare the effect of 12-month pharmacotherapy with a betablocker (BB) (bisoprolol and nebivolol) and a combination of BB with a mineralocorticoid receptor antagonist (bisoprolol+eplerenone, nebivolol+eplerenone) on following fibrosis markers: matrix metalloproteinases 1 and 9 (MMP-1, MMP-9)...

Full description

Saved in:

Bibliographic Details
Main Authors:	O. A. Osipova, E. V. Gosteva, T. P. Golivets, O. N. Belousova, O. A. Zemlyansky, M. V. Pokrovsky, A. I. Golovin, N. V. Grigorenko, A. A. Merezhko
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2021-11-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	heart failure myocardial fibrosis beta-blockers mineralocorticoid receptor antagonists
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/3068
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
by: WEN Runzhi, WANG Li, ZHAO Naiqian
Published: (2025-06-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods
by: L. V. Shekhovtsova, et al.
Published: (2020-11-01)

Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome
by: O. A. Osipova, et al.
Published: (2022-07-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review
by: A. A. Kuzmenko, et al.
Published: (2022-10-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
by: A. G. Evdokimova, et al.
Published: (2023-01-01)

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
by: Fei Y, et al.
Published: (2025-06-01)

Apparent Mineralocorticoid Excess Syndrome: Case Report
by: Alsaadoun SA, et al.
Published: (2025-06-01)

NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION
by: A. G. Dushina, et al.
Published: (2015-08-01)

Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting
by: Manochehr Amini, et al.
Published: (2025-07-01)

Beta-blockers in modern glaucoma therapy. Review
by: O. A. Kiseleva, et al.
Published: (2014-07-01)

Role of Gastric Acid Suppression Therapy in Erosive Esophagitis: From H2 Receptor Antagonists, Proton Pump Inhibitors, to Potassium-Competitive Acid Blockers
by: Ryan Herardi, et al.
Published: (2025-07-01)

TREATMENT OF HYPERTENSION IN PREGNANCY: GUIDELINES AND CLINICAL EXPERIENCE
by: O. V. Gaisenok, et al.
Published: (2015-09-01)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023-12-01)

To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure
by: Jinyu He, et al.
Published: (2025-07-01)

Combined use of beta-blockers and non-dihydropyridine calcium channel blockers: possible or contraindicated?
by: S. S. Yakushin, et al.
Published: (2024-02-01)

ANTAGONISTIC ACTIVITY OF ORAL BIOCENOSIS REPRESENTATIVES
by: A.V. Zaitsev, et al.
Published: (2021-09-01)

PRACTICE OF PRESCRIBING BETA-BLOCKERS AND ITS COMPLIANCE WITH CLINICAL GUIDELINES ACCORDING TO TWO REGISTERS OF CARDIOVASCULAR DISEASES
by: S. Yu. Martsevich, et al.
Published: (2016-06-01)

THE ROLE OF VASODILATING BETA-BLOCKERS IN PATIENTS WITH HYPERTENSION AND THE CARDIOMETABOLIC SYNDROME
by: A. A. Taylor, et al.
Published: (2011-08-01)

Beta-blocker and calcium-channel blocker therapy in patients with cardiovascular pathologies during post-COVID period
by: A. G. Arutyunov, et al.
Published: (2022-01-01)

EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

USE OF BETA-BLOCKERS IN THE PERIOPERATIVE PERIOD: HOW STRONG ARE THE EVIDENCES?
by: V. V. Samoylenko, et al.
Published: (2015-09-01)

HYPERTENSION IN POSTMENOPAUSAL WOMEN: RATIONALE FOR THE USE OF CALCIUM CHANNEL BLOCKERS IN ANTIHYPERTENSIVE THERAPY
by: O. A. Kislyak, et al.
Published: (2017-07-01)

A Modern View on the Treatment for Acute Calcium Channel Blocker Poisoning
by: A. Yu. Simonova, et al.
Published: (2024-09-01)

Challenges in hypotensive therapy: the role of calcium antagonists
by: E. O. Taratukhin, et al.
Published: (2013-04-01)

The use of mineralocorticoid antagonists in chronic heart failure
by: Andrea Szegedi, et al.
Published: (2025-07-01)

THE ROLE OF S-AMLODIPINE IN ARTERIAL HYPERTENSION THERAPY WITH COMBINATION OF CALCIUM CHANNEL BLOCKERS AND BETA-BLOCKERS
by: M. A. Maksimova, et al.
Published: (2015-09-01)

REGIONAL FEATURES OF BIFIDOBACTERIA ANTAGONISTIC ACTIVITY IN INTESTINAL MICROBIOTA OF CHILDREN LIVING IN SIBERIA
by: E. B. Rakova, et al.
Published: (2012-09-01)

Calcium regulation by calcium antagonists /
Published: (1982)

The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol
by: T. D. Giles
Published: (2011-12-01)

Heart rate-lowering antianginal medications: what determines their choice?
by: Yu. M. Lopatin
Published: (1970-01-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

The use of β-blockers in children in ICU – results of the interactive survey, a brief overview and own opinion
by: D. K. Аzovskiy, et al.
Published: (2020-06-01)

Efficacy of insulin therapy in severe poisoning with calcium channel blockers
by: A. Yu. Simonova, et al.
Published: (2023-12-01)

Calcium antagonists in patients with high cardiovascular risk
by: A. A. Garganeeva
Published: (2009-08-01)

CALCIUM ANTAGONISTS IN CLINICAL PRACTICE: FOCUS ON METABOLIC AND VASCULAR EFFECTS
by: D. V. Nebieridze
Published: (2015-12-01)